Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $253.30 | Total: $1,266.50 |
| 1 | 10 | $214.56 | Total: $2,145.60 |
| 1 | 25 | $181.78 | Total: $4,544.50 |
| 1 | 50 | $154.96 | Total: $7,748.00 |
| 1 | 100 | $134.10 | Total: $13,410.00 |
Overview
Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.
Chemical Properties
| Molecular Formula | C17H19N5O2 |
| Molecular Weight | 325.37 |
| CAS Numbers | 72732-56-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC=1C2=C(N=CC1CC3=C(OC)C=CC(OC)=C3)N=C(N)N=C2N |
Storage and Handling
0C Short Term, -20C Long Term
References
Sigel CW, et al. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987;[5] 111-120.